
## **Christian Schmidl**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2644606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut, 2021, 70, 157-169.	6.1	57
2	Cancer-associated cells release citrate to support tumour metastatic progression. Life Science Alliance, 2021, 4, e202000903.	1.3	21
3	Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory TÂcells. Immunity, 2021, 54, 702-720.e17.	6.6	78
4	Precursors for Nonlymphoid-Tissue Treg Cells Reside in Secondary Lymphoid Organs and Are Programmed by the Transcription Factor BATF. Immunity, 2020, 52, 295-312.e11.	6.6	140
5	Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. Cells, 2020, 9, 1484.	1.8	7
6	Structural cells are key regulators of organ-specific immune responses. Nature, 2020, 583, 296-302.	13.7	292
7	Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1. Nature Communications, 2020, 11, 402.	5.8	76
8	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nature Communications, 2020, 11, 577.	5.8	69
9	Genomeâ€wide cooperation of <scp>EMT</scp> transcription factor <scp>ZEB</scp> 1 with <scp>YAP</scp> and <scp>AP</scp> â€1 in breast cancer. EMBO Journal, 2020, 39, e103209.	3.5	104
10	Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers. Nature Genetics, 2019, 51, 1399-1410.	9.4	92
11	Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. Nature Chemical Biology, 2019, 15, 232-240.	3.9	34
12	High-throughput ChIPmentation: freely scalable, single day ChIPseq data generation from very low cell-numbers. BMC Genomics, 2019, 20, 59.	1.2	30
13	MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nature Genetics, 2019, 51, 990-998.	9.4	61
14	HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology, 2019, 156, 2313-2329.e7.	0.6	184
15	Rbpj expression in regulatory T cells is critical for restraining TH2 responses. Nature Communications, 2019, 10, 1621.	5.8	41
16	Epigenetic mechanisms regulating T-cell responses. Journal of Allergy and Clinical Immunology, 2018, 142, 728-743.	1.5	100
17	The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction. Biomedicines, 2018, 6, 25.	1.4	19
18	Pooled CRISPR screening with single-cell transcriptome readout. Nature Methods, 2017, 14, 297-301.	9.0	749

CHRISTIAN SCHMIDL

#	Article	IF	CITATIONS
19	FANTOM5 CAGE profiles of human and mouse samples. Scientific Data, 2017, 4, 170112.	2.4	195
20	Comprehensive genome and epigenome characterization of CHO cells in response to evolutionary pressures and over time. Biotechnology and Bioengineering, 2016, 113, 2241-2253.	1.7	112
21	Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. Nature Communications, 2016, 7, 11938.	5.8	131
22	Technical Advance: Transcription factor, promoter, and enhancer utilization in human myeloid cells. Journal of Leukocyte Biology, 2015, 97, 985-995.	1.5	23
23	Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1. Cell Reports, 2015, 10, 1082-1095.	2.9	183
24	ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors. Nature Methods, 2015, 12, 963-965.	9.0	417
25	Genome-wide identification of hypoxia-inducible factor-1 and -2 binding sites in hypoxic human macrophages alternatively activated by IL-10. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 10-22.	0.9	54
26	A promoter-level mammalian expression atlas. Nature, 2014, 507, 462-470.	13.7	1,838
27	An atlas of active enhancers across human cell types and tissues. Nature, 2014, 507, 455-461.	13.7	2,269
28	The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. Blood, 2014, 123, e68-e78.	0.6	77
29	Transcription and enhancer profiling in human monocyte subsets. Blood, 2014, 123, e90-e99.	0.6	157
30	Mechanisms of in vivo binding site selection of the hematopoietic master transcription factor PU.1. Nucleic Acids Research, 2013, 41, 6391-6402.	6.5	76
31	Dominant Th2 Differentiation of Human Regulatory T Cells upon Loss of FOXP3 Expression. Journal of Immunology, 2012, 188, 1275-1282.	0.4	60
32	Epigenetic reprogramming of the <i>RORC</i> locus during in vitro expansion is a distinctive feature of human memory but not naÃ <sup>-</sup> ve Treg. European Journal of Immunology, 2011, 41, 1491-1498.	1.6	57
33	Isolation of intact genomic DNA from FOXP3â€sorted human regulatory T cells for epigenetic analyses. European Journal of Immunology, 2010, 40, 1510-1512.	1.6	11
34	Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Research, 2009, 19, 1165-1174.	2.4	206
35	Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochemical and Biophysical Research Communications, 2006, 350, 731-735.	1.0	74